 |
|
Register for news updates on the MMAT/ADHD™ System clinical trials and other important milestones. | |
 |
|
ADHD is a common neurobiological disorder with multiple genetic and environmental origins. |
BioBehavioral Diagnostics Company (BioBDx) develops diagnostic systems that aid clinicians in the objective assessment of behavioral and neurobiological disorders. The company's lead product, the MMAT/ADHD™ System, is the first FDA cleared1 test that offers medical professionals an office-based capability to conduct rapid, precise and objective patient assessments to aid in the diagnosis of ADHD. Using the MMAT/ADHD™ System, healthcare professionals are able to precisely measure the three core symptoms of
ADHD (inattention, hyperactivity and impulsivity).
1. FDA clearance of this product does not in any way denote FDA approval of the device.
BioBDx Announces Availability of Quotient™ ADHD System
View Press Release
Larry Dubé, Medical Technology Industry Veteran, joins BioBehavioral Diagnostics as VP of Operations
View Press Release